Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs McCormick & Company, Incorporated (MKC) Price & Performance

Johnson & JohnsonTrade
McCormick & Company, IncorporatedTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs McCormick & Company, Incorporated — how do they compare? Johnson & Johnson trades at $260.22 (market cap $626.09B), while McCormick & Company, Incorporated trades at $52.75 (market cap $14.22B). The key difference: Johnson & Johnson is far larger — about 44× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.63%). Which is the better fit depends on your goals.

JNJMKC
Market Cap
$626.09B$14.22B
Volume
6,156,228
Sector
HealthConsumer Staples
52-Week High
$267.24$72.26
52-Week Low
$172.78$45.60
Enterprise Value
$654.37B$18.82B
Dividend Yield
2.06%3.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.

The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.

McCormick & Company, Incorporated

MKC trades at $53.13, up 0.32% today, with a bullish technical signal and strong profitability metrics including a 21.91% net income margin and 25.7% ROE. Recent Q2 2026 results beat expectations, driven by acquisitions and margin expansion. The pending Unilever Foods merger, expected to close in 2027, dominates news flow and offers transformative growth potential.

The outlook is positive, with a consensus price target of $59.67 implying 12% upside. Key opportunities include merger synergies and sustained dividend growth, while risks involve integration execution and soft consumer volumes. Analysts are mixed but lean bullish on valuation and strategic positioning.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About McCormick & Company, Incorporated

In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.

Read more on MKC